Log in to search using one of your social media accounts:

 

Paliperidone Manufacturer Issues Urgent Recall Paliperidone Manufacturer Issues Urgent Recall
Drug maker Teva has issued a voluntary recall of a single lot of paliperidone extended-release tablets because the drug failed test results for dissolution, which could reduce its efficacy.News Alerts (Source: Medscape Psychiatry Headlines)
Source: Medscape Psychiatry Headlines - June 16, 2017 Category: Psychiatry Tags: Psychiatry News Alert Source Type: news

Paliperidone Drug Manufacturer Issues Recall Paliperidone Drug Manufacturer Issues Recall
Drug maker Teva has issued a voluntary recall of a single lot of paliperidone extended-release tablets because the drug failed test results for dissolution, which could reduce its efficacy.News Alerts (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 15, 2017 Category: Consumer Health News Tags: Psychiatry News Alert Source Type: news

Teva Pharmaceuticals, USA Extends Voluntary Nationwide Recall to Consumer/User Level for One Lot of Paliperidone Extended-Release Tablets, 3mg, 90 Count Bottles Distributed Under the Actavis Pharma Inc. Label Due to Dissolution Test Failure
Teva Pharmaceuticals USA, Inc. (Teva) initiated a voluntary recall to retail-level on 05/31/2017 for one lot of Paliperidone Extended-Release Tablets, 3mg, 90 count bottles that was distributed under the Actavis Pharma Inc. label. In coordination with FDA, Teva is extending this recall to the CONSUMER/USER level. (Source: Food and Drug Administration)
Source: Food and Drug Administration - June 15, 2017 Category: Food Science Source Type: news

Effectiveness of paliperidone depot injection in seriously violent men with comorbid schizophrenia and dissocial personality disorder in a UK high-security hospital - Mortlock AM, Larkin F, Ross CC, Gupta N, Sengupta S, Das M.
BACKGROUND: High-security hospital patients are often complex in presentation and are characterized by treatment resistance, medication nonadherence and history of violence. Paliperidone is licensed both as an oral and depot antipsychotic medication in the... (Source: SafetyLit)
Source: SafetyLit - May 29, 2017 Category: International Medicine & Public Health Tags: Occupational Issues Source Type: news

Invega Sustenna (Paliperidone Palmitate Extended-Release Injectable Suspension) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - March 20, 2017 Category: Drugs & Pharmacology Source Type: news

Invega Trinza (Paliperidone Palmitate Extended-release Injectable Suspension) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - October 31, 2016 Category: Drugs & Pharmacology Source Type: news

Janssen-Cilag receives EC approval for Trevicta for maintenance treatment of schizophrenia
Johnson & Johnson subsidiary Janssen-Cilag International has been granted approval by the European Commission (EC) for the use of Trevicta (paliperidone palmitate a three-monthly injection) for the maintenance treatment of schizophrenia in adult pati… (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - June 1, 2016 Category: Pharmaceuticals Source Type: news

Invega Trinza (Paliperidone Palmitate Extended-release Injectable Suspension) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - March 7, 2016 Category: Drugs & Pharmacology Source Type: news

Safety of Vraylar vs. Other Antipsychotics Drugs Compared in New Drug...
Comparative safety research review covers Abilify (Bristol-Meyers), Fanapt (Novartis), INVEGA (J&J), Risperdal (J&J), Risperdal Consta (Janssen)(PRWeb October 26, 2015)Read the full story at http://www.prweb.com/releases/2015/10/prweb13042760.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - October 26, 2015 Category: Pharmaceuticals Source Type: news

Janssen submits European extension marketing authorisation application for paliperidone palmitate
First long-acting treatment to be administered four times a year for the treatment of schizophrenia in adults (Source: Pharmacy Europe)
Source: Pharmacy Europe - August 26, 2015 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Clinical trials Practical therapeutics Psychiatry Patient care antipsychotic Latest News long-acting therapy paliperidone palmitate schizophrenia xeplion Source Type: news

Invega Trinza (paliperidone palmitate) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - June 4, 2015 Category: Drugs & Pharmacology Source Type: news

Invega Trinza (paliperidone palmitate) for the Treatment for Schizophrenia
Invega Trinza (paliperidone palmitate), an atypical antipsychotic, is a three-month injection that is the first, and only, four-times-a-year drug indicated to treat schizophrenia . (Source: Drug Development Technology)
Source: Drug Development Technology - May 27, 2015 Category: Pharmaceuticals Source Type: news

FDA OKs 3-Month Drug for Schizophrenia
FDA OKs 3-Month Paliperidone (Invega Trinza) for Schizophrenia (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - May 20, 2015 Category: Journals (General) Source Type: news

FDA OKs 3-Month Paliperidone Injection for Schizophrenia FDA OKs 3-Month Paliperidone Injection for Schizophrenia
The quarterly treatment for schizophrenia must be preceded by monthly injections of Invega Sustenna for at least 4 months. FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 19, 2015 Category: Consumer Health News Tags: Psychiatry News Alert Source Type: news

J&J's Schizophrenia Drug Wins FDA Priority Review
The U.S. FDA has granted priority review to J&J's Janssen Pharmaceuticals' new drug application for antipsychotic Invega Trinza. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - May 19, 2015 Category: Pharmaceuticals Source Type: news

Long-term Injectable Antipsychotic Cuts Schizophrenia RelapseLong-term Injectable Antipsychotic Cuts Schizophrenia Relapse
The long-term formulation of paliperidone, which is currently under FDA review, may be the first atypical antipsychotic administered on a four-times-a-year dosing schedule. Medscape Medical News (Source: Medscape Psychiatry Headlines)
Source: Medscape Psychiatry Headlines - April 6, 2015 Category: Psychiatry Tags: Psychiatry News Source Type: news

Relapse Prevention of Schizophrenia: Paliperidone Depot vs. HaloperidolRelapse Prevention of Schizophrenia: Paliperidone Depot vs. Haloperidol
Long-acting injectable antipsychotics may be as effective in preventing relapse in schizophrenia as first-generation oral antipsychotics, but severity of side effects need to be taken into consideration. Evidence-Based Mental Health (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 2, 2015 Category: Consumer Health News Tags: Psychiatry Journal Article Source Type: news

Risperdal Lawsuit News: Mother Alleges Risperdal, Invega Caused Teen...
The Firm is representing numerous clients who have filed Risperdal lawsuits after allegedly developing gynecomastia, or male breast growth, due to the antipsychotic medication.(PRWeb December 04, 2014)Read the full story at http://www.prweb.com/releases/risperdal-lawsuit/invega-lawsuit/prweb12372984.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - December 5, 2014 Category: Pharmaceuticals Source Type: news

Janssen seeks FDA approval for its antipsychotic drug to treat schizophrenia
Janssen Research & Development has submitted a new drug application (NDA) for its three-month atypical antipsychotic paliperidone palmitate to the US Food and Drug Administration (FDA). (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - November 20, 2014 Category: Pharmaceuticals Source Type: news

European Commission approves Invega for treatment of schizophrenia in adolescents
Janssen-Cilag International’s Invega (paliperidone ER) has received the European Commission’s approval to extend its adult indication for treatment of schizophrenia to include adolescents aged 15 years and older. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - June 5, 2014 Category: Pharmaceuticals Source Type: news

Antipsychotic medications for schizophrenia compared: Similar results
Among adults with schizophrenia or schizoaffective disorder, treatment with the newer, more costly antipsychotic paliperidone palmitate, compared with the older antipsychotic haloperidol decanoate, found no significant difference on a measure of effectiveness, according to a recent study. Long-acting injectable antipsychotic medications are prescribed to reduce nonadherence to drug therapy and relapse in people diagnosed with a schizophrenia-spectrum disorder. The relative effectiveness of long-acting injectable versions of second-generation and older antipsychotic medications has not been previously assessed. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - May 20, 2014 Category: Science Source Type: news

Long-Acting Treatments for Schizophrenia
Schizophrenia has long presented treatment challenges for both patients who have the mental illness and the treatment providers who want to help them. Many medications prescribed for schizophrenia have traditionally not always been well-tolerated in patients, with sometimes significant side effects in some. Schizophrenia is a condition characterized by the person experiencing hallucinations and/or delusions, sometimes of a persecutory nature. It is usually first diagnosed in young adulthood — typically in a person’s 20s — and more often among men than women. Although usually severe in nature, it is also a...
Source: Psych Central - May 17, 2014 Category: Psychiatry Authors: John M. Grohol, Psy.D. Tags: Antipsychotics Atypical Antipsychotics Disorders General Medications Schizophrenia Treatment Invega Sustenna lai long-acting injectables Medication Noncompliance Paliperidone Psychiatry Psychotic relapse Risperidone Schizophr Source Type: news

Janssen submits sNDAs to FDA for Invega Sustenna to treat schizoaffective disorder
Janssen Pharmaceuticals has submitted supplemental new drug applications (sNDAs) to the US Food and Drug Administration (FDA) seeking approval for its once-monthly atypical long-acting antipsychotic Invega Sustenna (paliperidone palmitate) to treat s… (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - May 13, 2014 Category: Pharmaceuticals Source Type: news

Flood Law Group Now Available to Investigate Claims Related to...
Flood Law Group announced today that it is now available to investigate claims related to complications from taking prescription Invega extended release tablets. Invega, also known by its generic name...(PRWeb May 07, 2014)Read the full story at http://www.prweb.com/releases/invega-complications/flood-law-group/prweb11809557.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - May 8, 2014 Category: Pharmaceuticals Source Type: news

Long-acting Paliperidone Safe, Effective for Dual PsychosisLong-acting Paliperidone Safe, Effective for Dual Psychosis
Switching patients with dual psychosis from other long-acting and oral antipsychotic medications to long-acting injectable paliperidone palmitate is safe and effective, a small study suggests. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 11, 2014 Category: Consumer Health News Tags: Psychiatry News Source Type: news

Janssen reports PALMFlexS trial results of schizophrenia drug Xeplion
Janssen Pharmaceutica has reported encouraging results from the PALMFlexS study, which demonstrated the efficacy, safety and tolerability of Xeplion (paliperidone palmitate) in patients with schizophrenia at various stages of the disease. (Source: Drug Development Technology)
Source: Drug Development Technology - December 2, 2013 Category: Pharmaceuticals Source Type: news

New Data Show Efficacy, Safety and Tolerability of Xeplion(R) in Patients with Schizophrenia at Various Stages of the Disease
PALMFlexS study better reflects Xeplion® use in everyday clinical practice compared to previous clinical trials BEERSE, Belgium--(Healthcare Sales & Marketing Network)--Janssen Pharmaceutica NV has announced results of the PALMFlexS study during Th... BiopharmaceuticalsJanssen Pharmaceutica, Xeplion, paliperidone, Schizophrenia (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 29, 2013 Category: Pharmaceuticals Source Type: news

J&J Agrees to Pay $2.2B to Resolve Criminal/Civil Allegations
Justice Department officials alleged that J&J used illegal marketing tactics and kickbacks to persuade physicians and pharmacists to prescribe Risperdal and Invega (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - November 5, 2013 Category: Pharmaceuticals Source Type: news

Johnson & Johnson to pay $2.2B in U.S. health care fraud settlement
Allegations include paying kickbacks to physicians, pharmacies to recommend and prescribe antipsychotic drugs Risperdal and Invega, and heart failure drug Natrecor (Source: Health News: CBSNews.com)
Source: Health News: CBSNews.com - November 4, 2013 Category: Consumer Health News Source Type: news

Paliperidone palmitate: efficacy and cost effectiveness
Any treatment that offers even a small advantage in preventing relapse in schizophrenia must be clinically and economically advantageous. Paliperidone palmitate long-acting injection might be just such a treatment (Source: Pharmacy Europe)
Source: Pharmacy Europe - October 2, 2013 Category: Drugs & Pharmacology Authors: ebercott Tags: Featured Articles Source Type: news

Flexible-Dose Injectable Effective for Acute SchizophreniaFlexible-Dose Injectable Effective for Acute Schizophrenia
Flexible dosage of the injectable atypical antipsychotic paliperidone palmitate may be effective and well tolerated in patients with acute schizophrenia unsuccessfully treated with oral antipsychotics. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 11, 2013 Category: Consumer Health News Tags: Psychiatry News Source Type: news

Quick Facts About Invega - Paliperidone
Invega – generic name paliperidone – is an atypical antipsychotic approved for the treatment of schizophrenia and used off-label to combat acute mania in patients with bipolar disorder. It is derived from the active metabolite of Risperdal (risperidone). Here are a few important facts about this medication. (Source: About.com Bipolar Disorder)
Source: About.com Bipolar Disorder - June 15, 2013 Category: Psychiatry Authors: bipolar.guide at about.com Tags: health Source Type: news